ResearcherSichuan UniversityActive in the last 2 years

Xiaoying Li

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5141053220. Sources: OpenAlex.

Their work

Papers: 5 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 26

Papers, trials and grants by year

2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 5

Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation … First author DOI 10.1136/jitc-2026-015705 ↗
RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1 ↗
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-024-00970-6 ↗
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal a… First author DOI 10.1038/s41392-024-02031-8 ↗
Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies. Co-author DOI 10.3389/fimmu.2024.1326556 ↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dan Cao · 2 shared papers, 2025–2026 · strength 0.46
- Paper Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multic… DOI 10.1136/jitc-2026-015705 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chengjian Zhao · 2 shared papers, 2024–2025 · strength 0.42
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Wanting Hou · 2 shared papers, 2024–2025 · strength 0.42
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Junjie Xiong · 2 shared papers, 2024–2025 · strength 0.32
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Yi Cheng · 2 shared papers, 2024–2025 · strength 0.32
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Rui Wang · 2 shared papers, 2024–2025 · strength 0.32
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Yu Li · 1 shared paper, 2026 · strength 0.30
- Paper Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multic… DOI 10.1136/jitc-2026-015705 ↗
Haopeng Yu · 1 shared paper, 2026 · strength 0.30
- Paper Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multic… DOI 10.1136/jitc-2026-015705 ↗
Yuqi Wang · 1 shared paper, 2026 · strength 0.30
- Paper Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multic… DOI 10.1136/jitc-2026-015705 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.26
- Paper Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.26
- Paper Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhib… DOI 10.3389/fimmu.2024.1326556 ↗
Zixing Huang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chen Chang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Ke Cheng · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Huanji Xu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bole Tian · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaorui Zhu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Qingqing Leng · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chenyan Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bo Chen · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Heqi Yang · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Wanrui Lv · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Ke Cheng · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.